Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention

Summary

An increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with Western population. This study was designed to evaluate the relationship of bleeding to platelet function in East Asians undergoing percutaneous coronary intervention (PCI). Patients who had undergone uneventful PCI (n= 301) were prospectively enrolled and bleeding events were evaluated during dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Platelet function was measured during hospitalisation and at 30-day follow-up by light transmittance aggregometry (LTA) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) assay. During 30-day follow-up, 29.2 % of patients (n=88) experienced post-discharge Bleeding Academic Research Consortium (BARC) complications (24.6 % and 7.0 % of BARC type 1 and 2, respectively). Patients presenting with acute myocardial infarction had fewer episodes of type 1 BARC bleeding (odds ratio: 0.41; 95 % confidence interval: 0.22 to 0.76; p= 0.005). The cut-off of low platelet reactivity (LPR) (20 μM ADP-induced platelet aggregation ≤ 46.1 %; platelet reactivity index ≤ 45.1 %) was the independent determinant of type 2 BARC bleeding (odds ratio: 3.55 and 4.44; p= 0.009 and 0.002, respectively). The first 30-day BARC bleeding episodes were associated with an increased rate of subsequent premature DAPT discontinuation during one-year follow-up (4.7 % vs 11.4 %; odds ratio: 2.60; 95 % confidence interval: 1.04 to 6.50; p= 0.035). In conclusion, among East Asians, mild bleeding episodes are common early after PCI and are associated with premature DAPT discontinuation. Type 2 BARC bleeding episodes are associated with LPR cut-offs measured at 30 days post-discharge.

Keywords

Asia - clopidogrel - phenotype - genotype - bleeding

• References

• 1 Tantry US, Bonello L, Aradi D. et al. Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
• 2 Aradi D, Kirtane A, Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015; 36: 1762-1771.
• 3 Steg PG, Huber K, Andreotti F. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
• 4 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
• 5 Levine GN, Jeong YH, Goto S. et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11: 597-606.
• 6 Jeong YH, Tantry US, Gurbel P. What is the “East Asian Paradox”?. Cardiosource Interventional News 2012; 1: 38-39.
• 7 Jeong YH. “East Asian Paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep 2014; 16: 485.
• 8 Mak KH, Bhatt DL, Shao M. et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilisation, Management, and Avoidance (CHARISMA) study. Am Heart J 2009; 157: 658-665.
• 9 Shen AY, Yao JF, Brar SS. et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
• 10 Serebruany V, Rao SV, Silva MA. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post-discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235.
• 11 Kim IS, Jeong YH, Tantry US. et al. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. Am Heart J 2013; 166: 95-103.
• 12 Park Y, Jeong YH, Tantry US. et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J 2012; 33: 2151-2162.
• 13 Amin AP, Bachuwar A, Reid KJ. et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 2013; 61: 2130-2138.
• 14 East Asia. Wikipedia, the free encyclopedia. https://en.wikipedia.org/wiki/ East_Asia
• 15 Kitamura A, Nakagawa Y, Sato M. et al. Proportions of stroke subtypes among men and women > or =40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke 2006; 37: 1374-1378.
• 16 Scott SA, Sangkuhl K, Stein CM. et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94: 317-323.
• 17 Daemen J, Wenaweser P, Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
• 18 Kimura T, Morimoto T, Nakagawa Y. et al. j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.
• 19 Park DW, Yun SC, Lee SW. et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008; 1: 494-503.
• 20 Cuisset T, Grosdidier C, Loundou AD. et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA (predictor of bleedings with antiplatelet drugs) study. JACC Cardiovasc Interv 2013; 6: 854-863.
• 21 Kang HJ, Clare RM, Gao R. et al. PLATO Investigators. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 2015; 169: 899-905 e1.
• 22 Goto S, Huang CH, Park SJ. et al. Ticagrelor vs Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome: Randomized, Double-Blind, Phase III PHILO Study. Circ J 2015; 79: 2452-2460.
• 23 Saito S, Isshiki T, Kimura T. et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78: 1684-1692.
• 24 Ndrepepa G, Schuster T, Hadamitzky M. et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125: 1424-1431.
• 25 Matic DM, Milasinovic DG, Asanin MR. et al. Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention. Heart 2014; 100: 146-152.
• 26 Kikkert WJ, van Geloven N, van der Laan MH. et al. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI, GUSTO, and ISTH bleeding classifications. J Am Coll Cardiol 2014; 63: 1866-1875.
• 27 Roy P, Bonello L, Torguson R. et al. Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008; 102: 1614-1617.
• 28 Alexopoulos D, Xanthopoulou I, Deftereos S. et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 2014; 167: 68-76 e2.
• 29 Vranckx P, Leonardi S, Tebaldi M. et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J 2014; 35: 2524-2529.
• 30 Ben-Dor I, Torguson R, Scheinowitz M. et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drugeluting stents. Am Heart J 2010; 159: 871-875.
• 31 Dichiara J, Bliden KP, Tantry US. et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007; 18: 414-423.
• 32 Angiolillo DJ, Bernardo E, Zanoni M. et al. Impact of insulin receptor substrate- 1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011; 58: 30-39.
• 33 Marcucci R, Gori AM, Paniccia R. et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104: 279-286.
• 34 Shuldiner AR, O’Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
• 35 Stone GW, Witzenbichler B, Weisz G. et al. ADAPT-DES Investigators; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-623.
• 36 Tantry US, Bliden KP, Suarez TA. et al. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets 2010; 21: 360-367.
• 37 Park DW, Ahn JM, Song HG. et al. Differential prognostic impact of high ontreatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2013; 165: 34-42 e1.